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ABSTRACT 
Diabetes is a chronic and serious public health concern affecting millions of people around 
the globe. For effective prevention understanding of modifiable risk factors is fundamental. 
For type 2 diabetes these risk factors are well-described. However, for autoimmune diabetes 
such as type 1 diabetes, information is essentially missing. LADA, latent autoimmune 
diabetes in adults is suggested to be a hybrid of type 1 and type 2 diabetes and despite being 
common, its risk factors are scarcely investigated. Thus, the aim of this thesis was to add new 
understanding to the aetiology of LADA in relation to birthweight, overweight, obesity, 
family history of diabetes (FHD) and genes as well as the interaction between these factors in 
relation to the risk of LADA and how this compares with type 2 diabetes.  
The analyses were based on data from two large population based studies: ESTRID, an 
ongoing case-control study from Sweden including incident cases of diabetes and randomly 
selected controls (≥35 years of age) and HUNT, a prospective study from Norway with 
incident cases of diabetes and 22 years of follow-up. LADA was defined by the criteria that 
age at initial diagnosis is at least ≥35 years old and glutamic acid decarboxylase antibody 
(GADA) positivity. In ESTRID LADA patients also had C-peptide levels indicating residual 
insulin secretion. Patients ≥35 years of age with GADA negativity were considered to have 
type 2 diabetes. Information on birthweight, body mass index (BMI kg/m
2
) and FHD was 
self-reported in ESTRID. In HUNT, information on BMI was collected at the baseline 
medical examination.  
Our results indicate that heredity is primarily linked to FHD of type 1 diabetes (Relative risk 
[RR] 5.75; 95% confidence interval [CI] 3.23-10.25) but is also associated with FHD of type 
2 diabetes (RR 1.89; CI 1.45-2.47). Furthermore, our findings suggest that obesity (BMI ≥30) 
increases the risk of LADA 3-6 fold, although the risk was not as marked as for type 2 
diabetes (10-19 fold increased risk). In line with this, the risk of LADA was greater in 
individuals with low GADA but present also among those with higher degree of 
autoimmunity. Notably, our analyses indicate that 31-56% of all LADA patients may be 
prevented by keeping a normal weight (BMI <25). The greatest risk of LADA was seen in 
those with overweight in combination with HLA genes associated with autoimmunity (RR 
7.59, CI 5.27-10.93), with attributable proportion due to interaction (AP) estimated to 0.29 
(CI 0.10-0.47). Additionally, type 2 diabetes risk genes interacted with overweight in relation 
to LADA; TCF7L2 (AP=0.31, CI 0.09-0.52) and FTO (AP=0.38, CI 0.15-0.61). Moreover, 
low birthweight was associated with a more than 2-fold increased risk of LADA and type 2 
diabetes, with the strongest risk in those with low birthweight in combination with adult 
overweight; LADA, RR 3.26 (CI 1.69, 6.29); and type 2 diabetes, RR 39.93 (CI 19.27, 
82.71). In conclusion, results from this thesis indicate that LADA is associated with risk 
factors linked to insulin resistance and type 2 diabetes while genetic susceptibility is linked 
foremost to genes associated with autoimmunity and type 1 diabetes. Importantly, our 
findings suggest that LADA in part may be prevented by keeping a healthy weight. 
  
  
SAMMANFATTNING PÅ SVENSKA 
Diabetes är en kronisk och mycket vanlig sjukdom som kännetecknas av förhöjda 
blodsockernivåer (hyperglykemi). Sjukdomen orsakas av total brist på, eller delvis minskad 
utsöndring av hormonet insulin från bukspottkörtelns beta-celler. Insulinet behövs för att 
kroppens celler ska kunna ta upp energi från födan. Andra faktorer bakom diabetes är 
minskad insulinkänslighet i viktiga metabola organ som muskler, fettvävnad och lever. 
Diabetes är kopplat till ökad risk för hjärtsjukdom och stroke. Även risken för 
synnedsättning, njursjukdomar samt andra komplikationer, som beror på defekter i små och 
stora blodkärl eller nervskador, ökar till följd av kronisk hyperglykemi.  
Traditionellt sett brukar diabetes delas in i typ 1-diabetes (vanligast hos barn) och typ 2-
diabetes (vanligast hos vuxna). Det som framförallt utmärker typ 1-diabetes är mer eller 
mindre total insulinbrist, orsakad av en autoimmun reaktion d.v.s. där kroppens eget 
immunförsvar av okänd anledning förstör de insulinproducerande beta-cellerna. Hos personer 
med typ 2-diabetes producerar bukspottkörteln för lite insulin eller att kroppen inte kan 
använda insulinet på ett tillräckligt effektivt sätt (insulinresistens). Ny forskning visar dock att 
denna indelning kan vara alltför grov. Diabetes är i själva verket en betydligt mer heterogen 
sjukdom med flera undergrupper. En av dessa är LADA, latent autoimmun diabetes hos 
vuxna.  Man beräknar att ungefär 5-10 % av alla diabetespatienter i Europa har denna variant. 
LADA föreslås vara en blandning av både typ 1-diabetes (autoimmunitet) och typ 2-diabetes 
(insulinresistens). Hittills är forskning om riskfaktorer för LADA nästan obefintlig men 
hypotesen är att miljöfaktorer eller livsstil kan vara viktiga delar i etiologin. För att ta reda på 
mer om orsakerna bakom LADA var syftet med denna avhandling att undersöka risken i 
relation till födelsevikt, ärftlighet, övervikt/fetma och gener samt interaktion dem emellan. 
För att undersöka detta analyserades data från två stora befolkningsstudier, den svenska 
ESTRID-studien och den norska HUNT-studien. 
I delarbete I var syftet att undersöka sambandet mellan födelsevikt och risken för LADA och 
typ 2-diabetes med data från ESTRID. Resultatet tyder på att låg födelsevikt (<3 kg) 
fördubblar risken för både LADA och typ 2-diabetes jämfört med dem som hade hög 
födelsevikt (≥4 kg). Studien indikerar att det framförallt är miljöfaktorer under fosterstadiet 
t.ex. mammans diet eller rökning och inte gener som ligger bakom den förhöjda risken. Detta 
kan leda till permanenta metabola förändringar hos fostret som får både minskad 
insulinfrisättning och insulinkänslighet. Låg födelsevikt har även föreslagits öka risken för 
övervikt. I linje med detta sågs i vår studie en 3 gånger högre risk för LADA hos personer 
med låg födelsevikt och övervikt i vuxen ålder, jämfört med personer som var normalviktiga 
och med en födelsevikt på minst 3 kg. Denna dubbla börda, låg födelsevikt och övervikt, var 
associerad med en 40 gånger ökad risk för typ 2-diabetes.  
I delarbete II undersöktes om ärftlighet ökar sannolikheten för LADA och typ 2-diabetes. 
Resultaten tyder på att risken för LADA framförallt är kopplad till typ 1-diabetes i familjen; 6 
gånger ökad risk sågs hos dem med mamma, pappa, syskon eller barn med typ 1-diabetes. 
Risken var dock även förhöjd med typ 2-diabetes i släkten där en näst intill fördubblad risk 
sågs. Individer med LADA och ärftlighet för typ 1-diabetes hade även en högre grad av 
autoimmunitet och fler hade HLA-riskgener (högriskgener för typ 1-diabetes) jämfört med 
LADA-patienter med typ 2-diabetes i släkten. Risken för typ 2-diabetes var kopplad till typ 2 
men inte till typ 1-diabetes i släkten, vilket är i linje med tidigare studier. 
I delarbete III använde vi data från både ESTRID och HUNT för att utforska sambandet 
mellan LADA, övervikt och fetma.  Resultaten visade att övervikt kan vara en stark riskfaktor 
för LADA. Individer med fetma (body mass index [BMI] ≥30) löpte en 3-6 gånger högre risk 
jämfört med normalviktiga (BMI <25). Risken var dock inte lika markant som för typ 2-
diabetes där en 10-19 gånger ökad risk sågs hos dem med BMI ≥30. Vidare sågs den högsta 
risken för LADA och typ 2-diabetes hos dem med både övervikt och ärftlighet i släkten. I det 
här sammanhanget är det viktigt att påpeka att våra analyser indikerar att 31-56 % av alla 
LADA-patienter och 70-82% av alla med typ 2-diabetes kan förebygga sjukdomen genom att 
behålla en hälsosam vikt.  
I delarbete IV fortsatte vi att undersöka risken för LADA och typ 2-diabetes i förhållande till 
den kombinerade risken av ärftlighet och övervikt. Här studerade vi interaktion med 
högriskgener för typ 1- diabetes (HLA) och typ 2-diabetes (TCF7L2 och FTO). Risken var 
högst hos dem med HLA-gener (kopplade till autoimmunitet) där hela 8 gånger förhöjd risk 
sågs hos de som var överviktiga (BMI ≥25) jämfört med normalviktiga utan dessa riskgener. 
Beräkningarna tyder på att 29 % av alla LADA-patienter med både övervikt och HLA-gener 
kan tillskrivas växelverkan mellan dessa riskfaktorer. Vilket betyder att en lika stor andel 
LADA-fall kan förebyggas om övervikten inte uppstår. Även hos dem med övervikt i 
kombination med TCF7L2 och FTO syntes en klar interaktionseffekt. Gällande resultaten för 
typ 2- diabetes observerades en tydlig samverkan mellan övervikt och TCF7L2, men inte med 
vare med sig FTO eller HLA.  
Sammanfattningsvis stöder resultaten från avhandlingen att de faktorer som är kopplade till 
insulinresistens och typ 2-diabetes också utgör en ökad risk för LADA. Genetisk känslighet 
är däremot främst kopplad till autoimmunitet och typ 1-diabetes. Dessa fynd bidrar till det 
begränsade men gradvis ökande antalet studier som visar att livsstil spelar en viktig roll för 
förekomsten av LADA. Slutligen tyder våra resultat på att LADA delvis kan förebyggas med 
viktnedgång. Detta tycks även gälla för dem med genetisk känslighet. Andelen LADA-fall 
som kan förebyggas är sannolikt inte lika stor som för typ 2-diabetes.  
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1 INTRODUCTION 
Diabetes is a group of rapidly increasing metabolic disorders characterized by raised blood 
glucose levels (hyperglycaemia) [1]. The disease is caused by an inhibited or non-existing 
insulin secretion from the pancreatic β-cells, reduced insulin sensitivity in key metabolic 
organs (muscle, adipose tissue and liver) or both [2]. At the moment, diabetes is not possible 
to cure; primary prevention is therefore a prerequisite to reduce the diabetes burden. For 
effective prevention, knowledge of modifiable risk factors is essential. For type 2 diabetes 
such knowledge is extensive [3] and it has been shown that type 2 diabetes can be prevented 
through lifestyle modification [4, 5]. As for autoimmune diabetes, much research has 
addressed type 1 diabetes in children, but to date, only a few environmental risk factors have 
been identified [6]. For autoimmune diabetes with onset in adulthood, research is scarce. 
LADA, latent autoimmune diabetes in adults is the most common form of autoimmune 
diabetes in adults and accounts for 5-12% of all patients in Europe [7, 8]. LADA is a hybrid 
form of diabetes with a pathogenesis that includes autoimmune destruction of the β-cells, 
similar to type 1 diabetes, as well as features of type 2 diabetes, including insulin resistance. 
The aim of this thesis was to contribute to the limited knowledge of the aetiology of LADA 
by studying how low birthweight, family history, overweight/obesity and genes, as well as 
the interaction between these factors, affect the risk of LADA compared to type 2 diabetes. 
For this purpose we used data from two large population-based studies; the Swedish ESTRID 
study and the Norwegian HUNT study.   
 
32 BACKGROUND
2.1 DIABETES
Diabetes is the fastest growing disease worldwide and a major threat to public health, ranked
7th on the list of leading causes of death [1, 9]. In 2017, the global prevalence of diabetes was
estimated to be 8.4%, which is equivalent to 451 million affected individuals. This is
estimated to rise to 693 million by the year 2045 [10]. The increase is expected to be greater
in low- and middle-income in comparison with high-income countries [1]. Demographic and
cultural changes, including an ageing population and increasing prevalence of obesity and
sedentariness are believed to be the major forces behind this trend [11]. However, better
healthcare leading to improved life expectancy for individuals with diabetes has also
contributed to this increased prevalence [10, 12]. In Europe, the prevalence of diabetes is
8.8% in the adult population [1], while the prevalence in Sweden is slightly lower at 6.8%
[12]. Despite of improved medical treatment, the burden of the disease is enormous, with
large individual and societal consequences [13], primarily by disease related complications
and comorbidities, and an increased risk of premature death [11]. Because diabetes cannot be
cured, primary prevention strategies are key in reducing disease burden. Effective prevention
requires detailed information on risk factors. This knowledge is comprehensive for type 2
diabetes but limited for autoimmune diabetes.
Figure 2.1 Number of people with diabetes in different regions of the World in 2017 and
2045 (20-79 years). Adapted with permission from the IDF diabetes Atlas
(https://www.diabetesatlas.org/).
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2.1.1 Diagnosis 
Hyperglycaemia is the main symptom used to diagnose diabetes. According to guidelines 
from the American Diabetes Association (ADA) [14] and the World Health Organization 
(WHO) [15] hyperglycaemia is diagnosed on the basis of either a) fasting blood sugar levels 
≥7 mmol/L, b) 2 hour oral glucose tolerance test ≥11mmol/L, c) Hb1Ac ≥6.5% (48 
mmol/mol) or d) in patients with classic symptoms of hyperglycaemia or hyperglycaemic 
crisis, a random plasma glucose ≥11.1 mmol/L. 
 
2.1.2 Diabetes subtypes 
Diabetes is typically divided into two major subgroups: type 1 and type 2 diabetes. However, 
over the last decades it has become clear that diabetes is more heterogeneous than this sub-
division implies [16]. The concept of LADA, latent autoimmune diabetes in adults, was 
introduced in the nineties [17] and is a form of diabetes which shares clinical and genetic 
features with both type 1 (autoimmunity, HLA-conferred genetic susceptibility) and type 2 
diabetes (insulin resistance). It has been proposed that type 1 and type 2 diabetes can be 
regarded as two ends of a diabetes continuum containing several different phenotypes, 
distinguished only by various degrees of autoimmunity, insulin resistance, genetic 
susceptibility, age and obesity [16]. Recently, a completely new way of classifying the 
diabetes spectrum has been proposed, addressing foremost the diversity of type 2 diabetes 
[18]. This thesis focuses on LADA, which will be compared to type 1 and classical type 2 
diabetes. Other types of diabetes will not be covered in the thesis. 
2.1.2.1 Type 1 and type 2 diabetes 
Type 1 diabetes accounts for 7-12% of all cases of diabetes [1, 8]. It is the most common 
form of diabetes in children but can occur at any age [1, 19]. The incidence has increased 
dramatically over the latest decades. Although the greatest rise has been in North America 
[20], the highest incidence (aged <15 years) is found in Finland followed by Sweden and 
Kuwait. By contrast, the disorder is rare in China and Venezuela [21]. Type 2 diabetes is the 
most common form of diabetes and accounts for 75-85% of all cases [8, 18]. The prevalence 
depends on ethnicity and geographical area [1, 22] and while the highest prevalence is seen in 
Pima Indians [23], China and India have the highest number of affected individuals [1]. Type 
2 diabetes has traditionally been seen as a disease of the elderly but is unfortunately 
becoming more prevalent in adolescents and children [4, 28]. This trend has been linked to 
unhealthy lifestyle and the increasing childhood obesity [29, 30].   
  
  5 
2.1.2.2 LADA 
LADA may be the second most prevalent type of diabetes in adults, accounting for 3-12% of 
all diabetes patients [7]. The highest prevalence is seen in Europe where LADA is estimated 
to account for around one tenth of all patients initially classified as type 2 diabetes [24, 25]. 
Recent data from the Swedish ANDIS-study (All New Diabetics in Skåne) [8] including 
>10,000 incident diagnoses, indicates that LADA accounts for 5% of all patients (Figure 2.2). 
 
2.1.3 Pathogenesis 
2.1.3.1 Type 1 diabetes 
Type 1 diabetes is characterized by insulin deficiency caused by a T-cell mediated 
autoimmune reaction towards the insulin producing β-cells of the pancreas [26]. Onset is 
typically rapid with an acute and lifelong need of insulin treatment [27]. The autoimmune 
process can be detected by circulating autoantibodies, which may be present several years 
prior to diagnoses [28]. There are four autoantibodies commonly associated with 
autoimmunity in type 1 diabetes, namely: antibodies directed against insulin (IAA), glutamic 
acid decarboxylase (GADA), tyrosine phosphatase-like protein (islet antigen-2 [IA-2A]) and 
zinc transporter-8 (ZnT8A) [29]. Individuals with multiple antibodies are at especially high 
risk of type 1 diabetes, and these individuals commonly have an earlier age of onset [30, 31]. 
Type of antibody is also important for age at seroconversion with IAA usually being the first 
detected antibody in young children, while GADA is the primary autoimmune marker for 
onset at later ages [32].   
LADA 4.8%
Type 1 diabetes in adults 0.6%
Type 1 diabetes with relative insulin deficiency 0.7%
Type 1 diabetes with absolute insulin deficiency 6.0%
Type 2 diabetes in youth 2.1%
Type 2 diabetes with relative insulin deficiency 10.7%
Classical type 2 diabetes 72.5%
Secondary diabetes 1.3%
Unclassified 1.3%
Figure 2.2 Subtypes of diabetes in the ANDIS registry ( http://andis.ludc.med.lu.se/)  
 
 6 
2.1.3.2 Type 2 diabetes 
Insulin resistance in muscle, liver and adipose tissue plays a key role in the pathogenesis of 
type 2 diabetes. Insulin resistance leads to increased glucose production in the liver and 
reduced glucose uptake in muscle and adipose tissue [2]. Many mechanisms are involved e.g. 
genetic susceptibility, ectopic fat accumulation and systemic inflammation are all associated 
with reduced insulin sensitivity [2, 33]. β-cell dysfunction is however also needed for onset of 
type 2 diabetes. Besides a genetic predisposition, chronic hyperglycaemia and pancreatic fat 
accumulation put additional stress on the β-cells which leads to insufficient insulin secretion 
[2, 33]. Hyperglycaemia becomes manifest when the β-cells are no longer able to compensate 
for the increased need of insulin driven by insulin resistance [2]. 
2.1.3.3 LADA 
In 1977, Irvine and colleagues [34] identified a group of type 2 diabetes patients with 
pancreatic-islet-cell antibodies, which is indicative of an autoimmune pathogenesis. The term 
LADA was introduced by Tuomi et al. in 1993 [17] to better define this patient group that 
were autoantibody positive, but unlike type 1 diabetes patients, did not have a pronounced 
need for insulin at diagnosis. At the same time these patients had a clinical phenotype similar 
to that of type 2 diabetes, including adult onset and insulin resistance [17, 35]. Compared 
with type 1 diabetes patients that are often multi-antibody positive, individuals with LADA 
are typically positive for only one antibody, with GADA present in around 90% of the 
patients [25]. This results in a milder autoimmunity and a slowly progressive insulin-
dependence. Whether LADA should be regarded as a separate subtype of diabetes is still 
debated. While WHO [15] suggests that LADA is a hybrid diabetes type, ADA [14] proposes 
that LADA is a mild form of type 1 diabetes. 
Classification of LADA 
There is no universal definition of LADA. The presence of circulating islet autoantibodies, 
most often GADA, is however an absolute criterion, which is also how LADA is 
distinguished from type 2 diabetes. To separate LADA from type 1 diabetes, age at onset, 
typically above 30-35 years, is used. As supplementary criteria, to distinguish LADA from 
type 1 diabetes with adult onset, patients should be insulin independent at least 6-12 months 
after diagnosis [16]. Since the insulin criteria is subjective and depends on the decision made 
by the physician [36], it has also been suggested to use an indicator of remaining insulin 
production e.g. C-peptide to indicate a slow “latent” autoimmune process [18]. 
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Table 2.1 Clinical and genetic features of LADA in comparison with type 1 and type 2 diabetes 
 
Type 1  
diabetes 
LADA 
Type 2  
diabetes 
Age at onset Childhood  
(rare in adults) 
>30 years Adulthood  
(rare in children) 
Autoimmunity Strong Mild Absent 
β-cell function  Absent/low Present but declines Present  
Insulin resistance Rare Some Increased 
C-peptide Non detectable Decreased but 
detectable 
Present  
Insulin dependence At diagnosis >6 months after 
diagnosis 
None or years after 
diagnosis 
Genetic susceptibility HLA HLA 
TCF7L2, FTO? 
TCF7L2,  
FTO 
Adapted from Buzzetti et al. [7] and Tuomi et al. [16]. 
 
2.1.4 Co-morbidities and complications 
There is a serious risk of co-morbidities and disease related complications in individuals with 
diabetes [1]. In type 1 and type 2 diabetes chronic hyperglycaemia is found to damage blood 
vessels, eyes (retinopathy), kidneys (nephropathy) and nerves (neuropathy) [11]. Lower limb 
amputation as a consequence from peripheral nerve damage is 10-20 times more common in 
those with diabetes [1]. There is also an increased risk of macrovascular outcomes such as 
heart disease and stroke, and an increased overall risk of dying [11]. In Sweden the risk of 
excess mortality was ~4-fold for individuals with type 1 diabetes [37, 38] and ~2-fold for 
those with type 2 diabetes [39], compared with the general population. However, the risk 
widely varies depending on age at onset and number of cardiovascular related risk factors 
[40, 41]. Studies of complications in LADA are scarce. Still, even if it has been indicated that 
LADA patients have healthier metabolic profile than those with type 2 diabetes [42, 43], the 
risk of cardiovascular events does not seem to differ [42-46]. In some studies, the prevalence 
of neuropathy has even been suggested to be higher in individuals with LADA [7]. It is 
presumed that this is a consequence of more severe insulin deficiency and worse glycaemic 
control in individuals with LADA [7]. 
2.1.5 Diabetes management 
The purpose of diabetes management is primarily to keep blood glucose levels at an adequate 
level. For individuals with type 1 diabetes, lifelong insulin therapy is a necessity. For type 2 
diabetes, lifestyle modification (diet and physical activity) is the first line treatment followed 
by oral glucose lowering agents and injectables [47]. Metformin is the first hand choice while 
commonly used add-ons to metformin include sulfonylurea, thiazolidinediones, GLP-1 
receptor agonists and DPP-4 and SGLT2 inhibitors. However, if neither of these treatments 
suffice in stopping rising glucose levels, insulin injections may be required [47]. Alongside 
this, management of blood pressure and lipids may be needed to reduce macro and 
microvascular complications and mortality [47]. For LADA, the best treatment regimen is 
unclear. Most patients are initially treated with oral glucose lowering drugs [7] but because β-
cell deficiency typically progresses faster in LADA than in type 2 diabetes [48] it is currently 
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unclear whether insulin should be initiated at diagnosis [49]. Several intervention studies with 
LADA patients have been conducted to try to understand this, but they have left inconclusive 
answers [50, 51]. However, this topic will not be further discussed in the thesis. 
 
2.2 GENETICS 
2.2.1 Type 1 diabetes 
There is a known strong association between type 1 diabetes and DR and DQ genes within 
the human leukocyte antigen (HLA) complex on the short arm of chromosome 6 [52]. The 
HLA region is involved in the immune response; the DR and DQ encode cell-surface proteins 
which are involved in the presentation of antigens to T-lymphocytes. Polymorphisms are 
associated with insulin deficiency, presumably by an autoimmune-induced destruction of the 
β-cells [53]. HLA haplotypes DRB1*04:xx-DQA1*03:01-DQB1*03:02 (DR4-DQ8) and 
DRB1*03:01-DQA1*05:01-DQB1*02:01 (DR3-DRQ2) are the strongest predictors and the 
risk is particularly high when these are inherited together [52]. However, the frequency of 
these haplotypes in newly diagnosed patients decreases with age [54]. The HLA haplotypes 
are reported to account for approximately 50% of the familial aggregation of type 1 diabetes 
[55].There are also HLA haplotypes associated with protective effects including 
DRB1*15:01 (DR2)- DQA1*01:02-DQB1*06:02 [52]. Subsequent linkage and genome-wide 
association studies (GWAS) have found more than 60 loci outside the HLA system [56], such 
as the insulin gene (INS), PTPN22, CTLA-4, IL2RA and SH2B3, are associated with type 1 
diabetes [52]. In all, results from genetic studies explain about 80% of the heritability in type 
1 diabetes [57]. 
2.2.2 Type 2 diabetes 
Following the introduction of GWAS technique in 2007 rapid breakthroughs in knowledge of 
the genes contributing to type 2 diabetes were made. Today, more than 400 genetic loci 
linked to type 2 diabetes have been identified [58]. Still, together these genes explain less 
than 15% of the heritability of type 2 diabetes [57]. The strongest genetic effect is conferred 
by variants in the transcription factor 7–like 2 (TCF7L2) gene encoding a protein involved in 
the Wnt signalling pathway, which induce the transcription of several other genes such as 
those for insulin [59-61]. The rs7903146 variant explains most of the association and carrying 
the T-allele is associated with a ~30% increased risk of type 2 diabetes [62]. The majority of 
genes identified to date, including variants of TCF7L2, affect type 2 diabetes by impaired 
insulin secretion [63]. However some genes, including variants of the fat mass and obesity-
associated (FTO) gene, modify disease risk by insulin action [63]. In FTO, the risk is 
presumably mediated by greater overall energy intake and increased body fat [64]. 
2.2.3 LADA 
LADA is, similar to type 1 diabetes, strongly associated with high-risk variants in the HLA 
region, in particularly with variants of the DR and DQ loci [48, 65-69], although, with weaker 
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effect estimates for LADA [70]. The frequency of these high-risk genotypes is further related 
to degree of autoimmunity with strongest associations in LADA patients with higher GADA 
levels [67, 71]. Although there are some conflicting results [70], non-HLA loci linked to type 
1 diabetes including variants in PTPN22, INS and SH2B3 have been associated with LADA 
[68]. Additionally, LADA has been linked to some genes associated with type 2 diabetes, 
including TCF7L2 and FTO [70]. The association with TCF7L2 has been reported in several 
European studies [66, 72, 73] including in a meta-analysis with nearly 1000 LADA patients 
[73]. However not in all studies [67, 68] including the first GWAS of LADA which was 
recently published [69]. This may be due to power issues; while there was no association on a 
genome-wide level the nominal p-value was significant. It may also depend on the 
heterogeneity of the LADA patients; the associations with the TCF7L2 and FTO genes have 
been seen mainly in LADA with low GADA titre [67, 72]. 
2.3 ENVIRONMENTAL FACTORS 
2.3.1 Type 1 diabetes 
Few environmental risk factors for type 1 diabetes have been fully established. Study results 
have been difficult to replicate between populations and many contradicting findings have 
been presented [74]. Moreover, prevention studies have mostly been unsuccessful [75]. 
However, as only 10-15% of the patients have a first-degree family member with diabetes 
[76] environmental factors are strongly suspected in the aetiology. In further support, genetic 
changes alone cannot explain the rapid increase of type 1 diabetes over the latest decades. 
These potential risk factors may influence the risk of type 1 diabetes by directly triggering 
islet autoimmunity or they may accelerate disease progression in individuals with an ongoing 
autoimmune process. The most established trigger of autoimmunity to date is maternal 
enterovirus infection during the prenatal period, or direct exposure to these viruses in 
childhood [74]. Respiratory infections have in contrast been associated with both increased 
[77] and reduced risk (The hygiene hypothesis) [78]. Additional potential risk factors include 
higher maternal age and caesarean delivery [79] as well as stressful life events [80], 
suggestively mediated by increased cortisol levels and lower resistance to infections [81]. 
Early life dietary factors, including cow’s milk consumption, vitamin D (deficiency), low 
omega-3  fatty  acids and dietary toxins (nitrate and nitrite) [74] have further been implicated 
to trigger autoimmunity and β-cell apoptosis, mainly in individuals with a genetic 
predisposition. Collectively, these potential triggers have put forward the gut microbiota in 
the pathogenesis of type 1 diabetes [82]. The rapid increase in incidence has also coincided 
with the childhood obesity epidemic [83], implying that this may be an important promoter 
[84]. For instance high birthweight (discussed in section 2.4.2) [85, 86] mediated by maternal 
diabetes/obesity, high body mass index (BMI) (further discussed in section 2.4.3) [87, 88] 
and fast growth during the first years in life [89] have all been associated with increased risk 
of type 1 diabetes. 
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2.3.2 Type 2 diabetes 
A large body of research has successfully investigated the aetiology of type 2 diabetes and its 
prevention. Excessive weight has been identified as the major risk factor [11]. The hallmark 
of type 2 diabetes, insulin resistance, is partly viewed as an effect of general obesity, but it is 
hypothesized that abdominal body fat may be more important (further discussed in section 
2.4.3) [90, 91]. Other risk factors are low physical activity [92], sedentary lifestyle and hours 
of TV-watching (independent of total activity) [93] and smoking [94]. Diet has further been 
identified to play a fundamental role in the aetiology with excess risk associated with a high-
fat and low fibre diet, and consumption of red and processed meat and sugar sweetened 
beverages [95]. In contrast, moderate alcohol consumption [96], high coffee consumption 
[95] and foods associated with the Mediterranean diet, including fruit and vegetables and 
nuts, are associated with reduced risk [97].  High and low birthweight also appear important 
and both are associated with risk of type 2 diabetes (see section 2.4.2) [98-100]. 
Mechanistically, the majority of factors associated with type 2 diabetes are suggested to 
modify risk of disease by insulin sensitivity. Type 2 diabetes is known to be largely 
preventable with lifestyle interventions resulting in weight loss, including healthy diet and 
increased physical activity [4, 5]. 
2.3.3 LADA 
LADA is suggested to be a hybrid of type 1 and type 2 diabetes and consequently, risk factors 
may promote LADA both by way of promoting insulin resistance and/or by affecting β-cell 
autoimmunity. So far, limited attempts have been made to investigate potential risk factors in 
relation to LADA. The main reason is that few studies include both lifestyle information, 
antibody measurements to distinguish LADA from type 2 diabetes patients, and a suitable 
(diabetes-free) comparison group [101]. However results from the Norwegian HUNT and the 
Swedish ESTRID studies (described in detail in the methods section) imply that the aetiology 
of LADA may include lifestyle factors previously linked to type 2 diabetes such as 
overweight and obesity [102], physical inactivity [102], high consumption of sweetened 
beverages [103], smoking [104], sleep disturbances and low psychosocial well-being [105] 
and moderate alcohol intake (protective) [106]. These findings support the notion that insulin 
resistance may be important in the development of LADA. LADA has also been associated 
with factors suggested to increase the risk of type 1 diabetes including high education [107] 
and coffee consumption [108]. Previous studies further indicate that risk factors may differ 
for more and less autoimmune individuals, e.g. alcohol has been associated with a reduced 
risk of more type  2-like LADA but not more autoimmune type 1-like patients [109]. Studies 
are scarce hence there is a need for replications and extensions of these findings. 
Furthermore, the risk of developing LADA as a result of lifestyle factors likely depends on 
genetic susceptibility but few studies have investigated this notion in relation to LADA [110, 
111]. In this thesis, LADA risk will be studied in relation to family history of diabetes, low 
birthweight, and overweight/obesity including its interaction with genetic susceptibility. 
These factors have previously been associated with risk of type 1 and/or type 2 diabetes, as 
presented in the following section. 
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2.4 POTENTIAL RISK FACTORS STUDIED IN THE THESIS  
2.4.1 Family history of diabetes 
Family history covers both genetic and shared environmental factors and is a strong predictor 
of risk of diabetes [112]. 
2.4.1.1 Type 1 diabetes 
Familial clustering is a strong indicator of future risk of type 1 diabetes, first-degree relatives 
with diabetes increase the risk 9-fold [113]. The association is stronger for paternal diabetes 
[114, 115] but diminishes with age of the offspring. The strong genetic component is further 
illustrated by the 6-10% lifetime risk in dizygotic twins compared to >50% lifetime 
concordance rate in monozygotic twins [52, 76] 
2.4.1.2 Type 2 diabetes 
Diabetes in first-degree relatives confers a 3-fold increased risk of type 2 diabetes [112] and it 
has been suggested that the risk is higher if the mother has the disease, rather than the father 
[63]. A strong familial effect is further supported by twin studies indicating a concordance 
rate of 20-30% in dizygotic and ~70% in monozygotic twin pairs [63]. The heritability 
estimates are stronger at younger age and in lean compared to obese individuals [116]. 
2.4.1.3 LADA 
Reports on family history in LADA are scarce but cross-sectional studies indicate a high 
prevalence [117, 118]. A 4-fold increased risk in those with a family history of any type of 
diabetes was found in the HUNT study [119], whereas the risk was increased 2-fold in the 
Finnish Botnia study [120]. Because LADA is suggested to be hybrid form of diabetes [16], 
which is also supported by evidence from some genetic studies [70], family history of both 
type 1 and type 2 diabetes may potentially promote LADA. Findings of a few smaller studies 
support this hypothesis [121-124]. Furthermore, prospective data from the Botnia study found 
that a mix of both forms of diabetes in the family was associated with a 2-fold increased risk 
of non-insulin requiring diabetes [120]. However, the relative importance of family history of 
type 1 versus type 2 diabetes in the aetiology of LADA has not been explored. Other 
questions that remain to be investigated include the influence of female vs. male relatives, 
number and closeness of afflicted family members and underlying mechanisms, e.g. the 
influence of family history of diabetes on indicators of autoimmunity and insulin resistance. 
2.4.2 Birthweight 
The intrauterine environment has been suggested to be essential in predicting various 
metabolic disorders, including diabetes [125]. The association between parental 
environmental factors such as diet, body composition, smoking and stress during time of 
conception, adverse foetal developmental and later chronic disease of the offspring, support 
this notion [126]. Epigenetic and metabolic reprogramming in response to these in utero 
stressors provide a mechanistic link [127].   
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2.4.2.1 Type 1 diabetes 
With regard to type 1 diabetes a modest link to high birthweight (macrosomia) has been 
documented in two meta-analyses [85, 86] and this association was replicated in a recent 
nationwide Swedish study [128]. It was suggested that this reflects overstimulation of the 
foetal pancreatic β-cells from maternal diabetes/obesity during pregnancy [129] which in 
turn, has been associated with higher birthweight and type 1 diabetes [128]. This is likely an 
effect from maternal hyperglycaemia stimulating foetal insulin secretion; one of the key 
determinants of foetal growth [130]. A similar association with birthweight has been 
documented in other autoimmune diseases, including rheumatoid arthritis [131, 132]. 
2.4.2.2 Type 2 diabetes 
It is well documented that both high and low birthweight increase the risk of type 2 diabetes 
[98-100].  As similar to type 1 diabetes, high birthweight correlates with gestational diabetes 
and maternal adiposity [133]. This leads offspring to reduced β-cell volume and function and 
impaired insulin action [129] with long-term metabolic consequences such as increased risk 
of obesity and type 2 diabetes [134]. However, genetics [135] and shared life-style factors 
within families [126] have also been suggested to underlie the association. It is hypothesised 
that low birthweight is an indicator of poor nutrition of the foetus, leading to β-cell 
dysfunction, impaired mitochondrial oxidation in muscles and reduced insulin sensitivity 
[126]. The ‘thrifty phenotype hypothesis’ introduced by Hales and Barker in 1992 [136], 
suggests that low birthweight leads to metabolic disturbances and an energy saving 
phenotype that when met with rapid postnatal growth, increases the risk of later obesity, 
insulin resistance and type 2 diabetes. Several studies support this hypothesis in relation to 
the risk of type 2 diabetes [137]. In further support, low birthweight in combination with 
adult overweight has been shown to synergistically increase the risk of myocardial infarction 
[138] and metabolic syndrome [139]. Genetic factors may also mediate low birthweight and 
type 2 diabetes and genes inherited from the father are suggested to be most important [140].   
2.4.2.3 LADA 
One may hypothesise that low birthweight increases the risk of LADA by way of promoting 
insulin resistance and furthermore, that low birthweight may interact with adult overweight in 
the aetiology of LADA, similarly to what has been reported in type 2 diabetes. In this thesis, 
birthweight was investigated in relation to the risk of LADA for the first time.    
2.4.3 Overweight and obesity 
The global prevalence of overweight and obesity is 39% in the adult population, and the 
prevalence has tripled in children sine the seventies [13]. Excessive weight is the main cause 
of insulin resistance – among obese Caucasians 70% are presumed to be insulin resistant [91]. 
The detrimental effects of obesity are also genetically determined and differ over ethnic 
groups with Asians being insulin resistant at lower levels of obesity [90, 91]. 
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2.4.3.1 Type 1 diabetes 
Autoimmune diabetes has commonly been viewed as a non-obese form of diabetes. 
Nevertheless, according to several studies, high BMI [87, 88] and rapid growth during the 
first years in life [141, 142] are associated with an elevated risk of type 1 diabetes. The 
‘accelerator hypothesis’ [143] proposes that adiposity increases insulin resistance and 
accelerates β-cell apoptosis in already at-risk individuals. It also proposes that insulin 
resistance is the common underlying feature of all types of diabetes. A role for excessive 
weight in the aetiology of type 1 diabetes is further strengthened by the parallel increase in 
childhood obesity and type 1 diabetes incidence [83, 84, 144]. Obesity may also affect the 
risk by promoting β-cell autoimmunity; pro-inflammatory adipokines, released from 
excessive fat tissue have been shown to be involved in many immune mediating processes 
[145]. 
2.4.3.2 Type 2 diabetes 
Overweight and obesity are the single most important risk factors for type 2 diabetes [11]. A 
meta-analysis of prospective cohort studies found a 3-fold increased risk in overweight 
individuals, and a 7-fold increased risk in obese individuals [146]. The pathway between 
excessive weight and insulin resistance has been linked to a cross-talk between adipose 
tissue, skeletal muscle and liver [91] where the ability to store excessive fat subcutaneously is 
instrumental. The failure to expand adipocytes and adipose tissue in response to surplus 
calories will lead to accumulation of fat in ectopic depots such as liver, skeletal muscle and 
intra-abdominal (visceral fat) depots which is highly associated with insulin resistance in 
these organs. Abdominal fat has therefore been suggested to be far more detrimental than 
whole body obesity [90, 91]. Recent studies also suggest that functional changes in the gut 
microbiome (e.g. reduced diversity) may have a role in obesity and type 2 diabetes by way of 
reduced insulin sensitivity [147]. 
2.4.3.3 LADA 
Results from cross-sectional studies suggest that individuals with LADA have higher BMI 
than patients with type 1 diabetes but are leaner than patients with type 2 diabetes [48, 117, 
148-152]. The clinical phenotype within LADA also varies and patients with low GADA 
levels usually have higher BMI than those with high GADA levels. As demonstrated above, 
obesity has been linked both to insulin resistance as well as insulin secretion. Thus the 
heterogeneity of LADA suggests that the risk may differ depending on level of autoimmunity 
and that several pathways could be involved. Previous analyses, based on a subset of the 
HUNT study, suggest that overweight and obesity are as strong risk factors for LADA as for 
type 2 diabetes [102]. However this study was based on only 81 cases of LADA and 
replications and extensions of these findings are warranted. It is still unknown if the 
association also relates to more autoimmune forms of LADA, and if overweight interacts 
with family history or genetic susceptibility in relation to the risk of LADA. 
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2.4.4 Interaction between overweight, obesity and genes 
A potential relationship with excessive weight and LADA may depend on genetic 
susceptibility. Few studies have investigated gene-overweight interaction in relation to 
autoimmune diabetes. However, a Swedish study found that type 1 diabetes in children with 
low-risk HLA DQ haplotypes was associated with higher prevalence of overweight/obesity in 
a synergistic manner [153]. Further support came from a study of multiple sclerosis in which 
the authors reported a striking additive interaction between obesity and the high risk HLA-
DRB1*15 genotype [154]. For type 2 diabetes, large-scale studies have found interaction 
between a genetic risk score, BMI status [155] and waist circumference [156]. Studies of 
specific genotypes are scarce. Nevertheless, a Chinese study recently reported a strong 
interaction between TCF7L2 risk genotype (rs290487) and BMI status /waist circumference 
in relation to type 2 diabetes risk [157].  The FTO gene is also interesting as the risk variants 
seem to modify eating behaviour and body composition [64], at the same time, the risk of 
type 2 diabetes attenuates with physical activity  [158, 159]. Studies of family history further 
support a strong gene-overweight interaction in the aetiology of type 2 diabetes [160-162].  
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3 AIMS 
The overarching aim of this thesis is to provide new information on the influence of 
birthweight, overweight and obesity, family history and genes and their interplay on the risk 
of LADA.  
 
The specific aims were as follows: 
I. To study the risk of LADA and type 2 diabetes in relation to birthweight, and 
potential interaction between low birthweight and adult overweight (Paper I).  
 
II. To study the role of family history of type 1 and type 2 diabetes in relation to the 
risk of LADA and type 2 diabetes (Paper II). 
 
III. To study the impact of overweight and obesity on the risk of LADA and type 2 
diabetes and to assess potential interaction between overweight and family history 
of diabetes (Paper III).  
 
IV. To study the risk of LADA and type 2 diabetes related to the interaction of 
overweight and genetic susceptibility as indicated by high-risk genotypes of HLA 
DR-DQ, TCF7L2 and FTO (Paper IV). 
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4 MATERIALS AND METHODS
This thesis is based on data from two large Scandinavian studies: The Swedish ESTRID
Study (Epidemiological study of risk factors for LADA and type 2 diabetes);
https://ki.se/imm/estrid (paper I-IV) and the Norwegian HUNT Study (Nord-Trøndelag
Health Study): https://www.ntnu.edu/hunt (paper III -IV). Together these two data materials
comprise the two largest population-based studies, to date, investigating environmental risk
factors for LADA.
4.1 THE ESTRID STUDY (PAPER I, II, III, IV)
4.1.1 Study design
ESTRID is an ongoing population-based case-control study, initiated in 2010, aiming at
clarifying how lifestyle factors, alone and in combination with genes, affect the development
of LADA compared with type 2 diabetes. ESTRID (Figure 4.1) continuously recruit all
incident cases of LADA and a random sample of incident cases of type 2 diabetes (4 per
LADA case) from two diabetes registers: ANDIS (All New Diabetics in Scania;
http://andis.ludc.med.lu.se), and ANDiU (All New Diabetics in Uppsala;
http://www.andiu.se). The aim of these registers is to characterize all new cases of diabetes
diagnosed at health centres and hospitals in Scania and Uppsala based on detailed clinical and
genetic information. Diabetes-free population-based controls (six per every one case of
LADA), ≥35 years of age to match the age criteria of the LADA patients, are enrolled by
random sampling from the Swedish national population register using incidence density
methodology [163].
All inhabitants of Skåne County
(~1.3 million)
All inhabitants of Uppsala County
(~350,000)
-
LADA cases
Type 2 diabetes cases
-
Figure 4.1 Flow chart of the ESTRID Study.
All inhabitants of Skåne County
(~1.3 million)
A l inha i ppsala County
, 0)
ANDIS registry
Clinical investigation
Blood samples
Controls
Random sample of
diabetes-free
individuals
LADA cases
Type 2 diabetes cases
EIRA Study
Controls with
genetic information
ESTRID Study
LADA
Type 2 diabetes
Controls
Questionnaire information (cases and controls): health, family history and lifestyle factors
Clinical and genetic data (cases): GADA, C-peptide, genotypes, treatment
ANDiU registry
Clinical investigation
Blood samples
LADA cases
Type 2 diabetes cases
Controls
Random sample of
diabetes-free
individuals
All new cases
of diabetes
All new cases
of diabetes
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Since controls in ESTRID do not provide blood samples, for the BMI-gene interaction 
analysis in study IV, we used genetic controls from the EIRA (Epidemiological Investigation 
of Rheumatoid Arthritis; https://www.eirasweden.se) study (Figure 4.1) [164]. EIRA is based 
on the same case-control methodology as ESTRID and participants answer a very similar 
questionnaire. These control subjects, aged ≥35 years and free of diabetes and rheumatoid 
arthritis, are randomly selected from the Swedish population register and matched to the 
cases in ESTRID by age and sex.  
4.1.2 Study population 
Eligible in paper I were all participants included in ESTRID between September 2010 and 1 
July 2014 with self-reported information on birthweight (45.0% of the total study population 
could recall this information) and complete information on all confounders (age, sex, BMI 
and family history of diabetes [FHD]); incident cases of LADA; n=134 and type 2 diabetes; 
n=350, and diabetes-free controls; n=603.   
In paper II the analytical sample consisted of individuals recruited until 31 July 2015 with 
complete information on FHD and confounders (age, sex, BMI, smoking and education); 
incident cases of LADA; n=378 and type 2 diabetes; n=1 199, and diabetes-free controls; n=1 
484 (99.5% of the total sample).  
The study population in paper III was based on data from ESTRID gathered until July 2016 
and included all incident cases of LADA (n=425) and type 2 diabetes (n=1,420), and 
diabetes-free controls (n=1,704) with complete information on BMI and confounders (age, 
sex, FHD, smoking and physical activity), comprising 98.2% of the total study sample.  
Eligible in paper IV were all cases of LADA (n=394) and type 2 diabetes (n=1,290) included 
in ESTRID between September 2010 and July 2017 and all controls (n=2,656) from the 
EIRA study enrolled between 1996 and 2014 (free of diabetes and rheumatoid arthritis), with 
complete information on BMI and confounders (age, sex, smoking and physical activity) and 
with information on at least one of the genotypes of interest (HLA DR-DQ, TCF7L2-
rs7903146) or FTO-rs9939609). Comprising 62% of the total sample. 
4.1.3 Biochemical and clinical information 
Fasting blood samples from time of diagnosis were collected for all cases and analysed at the 
university laboratory of Skåne and Uppsala. Classification of diabetes subtype was based on 
age at onset, glutamic acid decarboxylase autoantibodies (GADA) and fasting C-peptide. 
GADA was analysed with ELISA (enzyme-linked immunosorbent assay; RSR Limited, 
Cardiff, UK) and at the cut-off level of 10.7 IU/ml, specificity and sensitivity of the assay 
were 98% and 84% respectively [165], values above 250 IU/ml were censored at 250 IU/ml. 
C-peptide level was analysed using the Cobas e 601 analyser (Roche Diagnostics, Mannheim, 
Germany) or IMMULITE 2000 (Siemens Healthcare Diagnostics Product Ldt., Llanberies, 
UK). Fasting blood glucose and C-peptide were used to calculate Homeostatic model 
assessment (HOMA) indices of insulin resistance, insulin sensitivity and β-cell function with 
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the HOMA2 calculator (Oxford Centre for Diabetes, Endocrinology & Metabolism. Diabetes 
Trial Unit). 
4.1.4 Classification of diabetes 
Patients were diagnosed within the health care system of each county according to national 
standard. LADA was classed as age ≥35 years at diabetes onset, GADA positivity (≥10 
IU/ml), and C-peptide level above the lower boundary of the normal range; ≥0.2 nmol/l 
(IMMULITE) or ≥0.3 nmol/l (Cobas). Type 2 diabetes were defined as age ≥35 years at 
diagnosis, GADA negativity (<10 IU/ml) and C-peptide >0.6 nmol/l (IMMULITE) or >0.72 
nmol/l (Cobas). 
4.1.5 Questionnaire information 
The questionnaire in ESTRID contains a variety of items on general health, heredity and 
lifestyle including queries on leisure time physical activity, smoking, alcohol and education.  
The survey is sent out in parallel to cases and their matched controls. Cases receive the 
questionnaire as soon as possible after diagnosis (median 5 months) and are specifically 
asked to provide information on lifestyle habits as they were before diagnosis. 
Birthweight (Paper I) 
Self-reported birthweight was collected from the questionnaire and categorized according to 
low (<3 kg), normal (≥3 to <4 kg) and high (≥4 kg) weight. By linkage to the Swedish 
medical birth register, we were able to validate the self-reported information for those born in 
1973 and onwards (r= 0.86, p<0.0001).   
Family history of diabetes (Paper II) 
Family members’ diabetes status was inquired by questions on diabetes in first-degree 
relatives (mother, father, sisters, brothers, sons and daughters) and maternal and paternal 
grandparents. Information on age at onset and insulin treatment was available and relatives 
<40 years at onset and with insulin treatment were classed as having type 1 diabetes or else as 
having type 2 diabetes. There was an additional question on total number of other second-
degree relatives (aunts, uncles, grandchildren, nephews, nieces) and first-degree cousins with 
diabetes. 
Body mass index (Paper III, IV) 
BMI was calculated using self-reported information on current weight and height as kg/m
2
. 
The patients were asked to report weight before onset of diabetes and this information 
showed high correlation with clinically gathered information from time of diagnosis (r=0.92, 
p<0.0001). BMI was categorised according to WHO’s definition as normal weight; <25 
kg/m
2
, overweight; 25–29.9 kg/m2 and obese; ≥30 kg/m2. 
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4.1.6 Genetic information 
For cases (Paper II, III and IV), genotyping was performed using blood DNA samples 
analysed with iPLEX Gold technology (Sequenom Laboratories, San Diego, CA, USA). 
Infinium CoreExome v1.1 (Illumina, San Diego, CA, USA) was used for imputation of 
missing genotypes based on the Haplotype Reference Consortium (http://www.haplotype-
reference-consortium.org/; version r1.1 2016) reference panel. All analyses were computed at 
the Lund University Diabetes Centre.  
For controls (Paper IV), blood DNA samples from the EIRA biobank were genotyped for 
HLA variants using an Infinium Illumina 300K immunochip custom array (Illumina, San 
Diego, CA, USA) while genotyping of TCF7L2 and FTO was based on GWAS data using the 
Illumina Global Screening array.  
Single nucleotide polymorphisms (SNPs) were used to identify carriers of high-risk variants 
of TCF7L2 (rs7903146 T-allele), FTO (rs9939609 A-allele) and HLA DRB1 and DQB1. For 
the HLA genotypes, three SNPs in the major histocompatibility complex (MHC) class II 
region (rs3104413, rs2854275, rs9273363) were combined to classify individuals as carriers 
of high (DR4/4, DR3/3, DR3/4, DR3/4-DQ8, DR4/4-DQ8, DR4/X-DQ8) or low/intermediate 
(DR4/X, DR3/X, DRX/X, DR4-DQ7) risk variants. This method has been validated with an 
overall accuracy of 99.3% [166]. 
 
4.2 THE HUNT STUDY (PAPER III, IV) 
4.2.1 Study design 
The HUNT Study (Figure 4.2) is a longitudinal study initiated with the overall aim of serving 
as a solid foundation for a large number of health related research topics [167]. The study 
comprises three separate health surveys conducted during the period 1984-2008: HUNT1 
(1984-86), HUNT2 (1995-97) and HUNT3 (2006-08)  to which the complete population aged 
≥20 years, living in the Norwegian County of Nord Trøndelag was invited to participate. The 
surveys included questionnaires on lifestyle and health related matters and a clinical 
examination which included anthropometrical measurements and blood sampling. The 
overall response rate in HUNT is high but declined over time with a 90.3%, 71.3% and 54% 
response rate in the HUNT1, HUNT2 and HUNT3 surveys respectively [167]. Among those 
still alive, 78% attended both in the HUNT1 and HUNT2 surveys while the proportion of re-
attenders between HUNT2 and HUNT3 was 70%. 
4.2.2 Study population 
Eligible for Paper III were all individuals attending at least two surveys, who were free of 
diabetes at baseline (HUNT1 or HUNT2), with complete baseline information on BMI, age, 
sex, FHD, physical activity and smoking (n=56,549). During 1,012,957 person-years of 
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follow-up (1984–2008) 147 incident cases of LADA and 2002 cases of type 2 diabetes were
identified. This information was available for 89% of the responders.
We also formed a sub-cohort of individuals participating in the HUNT2 and HUNT3 surveys
with complete information on waist and hip circumference (only available from baseline at
HUNT2) and covariates. During 463,670 person-years of follow-up, 51 cases of LADA and
1,038 cases of type 2 diabetes were identified.
Paper IV comprised 48,599 individuals who participated in at least two surveys, were free of
diabetes at baseline and with complete baseline information on BMI, age, sex, physical
activity and smoking and with data on at least one of the genotypes we were interested to
study (HLA, TCF7L2 or FTO). This included incident cases of LADA (n=131) and type 2
diabetes (n=1,901) and 886,120 person-years of follow-up (79% of the responders).
HUNT1 (1984-86)
Invited
Participated n=76885 (90%)
HUNT1-2
-97)
Invited n=92936
Participated n=66140 (71%)
-3
n= 37004
HUNT3 (2006-08)
Invited n= 94194
Participated n=50839 (54%)
Second investigation
Indiviudals self-reported diabetes
-
, ,
HUNT1-2-3 n=30754
All inhabitants of Nord Trøndelag County >20 old
, ,
Figure 4.2 Flow chart of the HUNT Study. Adapted from Krokstad et. al [167].
4.2.3 Biochemical analyses
At follow-up (HUNT2 or HUNT3) incident cases of diabetes were identified by self-report.
This information showed very high concordance with information from medical records
(>95%) [168]. Participants reporting diabetes were invited to a follow-up investigation during
which trained nurses probed for age at onset and diabetes treatment. Fasting blood samples
were also collected (median 4 years after diagnosis) and serum samples were analysed for
glucose, C-peptide and GADA titres. For those not attending the follow-up examination,
GADA was measured in non-fasting serum available from the HUNT biobank [67]. Glucose
was measured with a HemoCue monitor at Levanger Hospital, Levanger, Norway. C-peptide
HUNT1 (1984-86)
Invited n=85100
Participated n=76885
(90%)
•Questionnaires
•Clinical examination
HUNT1-2
n=46559
HUNT2 (1995-97)
Invited n=92936
Participated n=66140
(71%)
•Questionnaires
•Clinical examination
•Blood samples
HUNT2-3
n= 37004
HUNT3 (2006-08)
Invited n= 94194
Participated n=50839
(54%)
•Questionnaires
•Clinical examination
•Blood samples
HUNT1-2-3 forms a prospective cohort of ~60 000 diabetes-free individuals that can be
followed for 11-22-years for onset of diabetes.
Second investigation HUNT2 and HUNT3
Indiviudals with self-reported diabetes
Fasting blood sampling
• Glucose • C-peptide • GADA
Dead, emigrated,
disappeared
N=17389
LADA n=164
Type 2 diabetes n=2204
HUNT - 30754
All inhabitants of Nord Trøndelag County >20 years old
Dead, emigrated,
disappeared
N=12902
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was analysed with radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX, USA) 
and GADA with immunoprecipitation radioligand assay by translation labelled 
3
H-GAD65 
(NovoNordisk, Bagsværd, Denmark) at Aker Hospital, Oslo, Norway. GADA was reported 
as an index value relative to standard serum. The specificity (1.00) and sensitivity (0.64) of 
the GADA method was tested in the Islet Antibody Standardization Program 2003 workshop 
and the cut-off antibody index ≥0.08 for positivity (equivalent to ≥43 IU/ml according to the 
WHO standard) was chosen to attain the highest possible specificity with reasonable 
sensitivity. HOMA indices were calculated as in ESTRID, with the HOMA2 calculator 
(Oxford Centre for Diabetes, Endocrinology & Metabolism. Diabetes Trial Unit). 
4.2.4 Classification of diabetes 
LADA was defined as age at onset ≥35 years and with GADA positivity (≥43 IU/ml) but 
because treatment information was missing for 12% of the antibody positive cases we did not 
use the insulin criteria. By this definition we have unavoidably included also type 1 diabetes 
patients with adult onset in our LADA group. However 81.7% of those with this information 
reported that they were without insulin treatment the year after diagnosis, indicating that the 
proportion of misclassified type 1 diabetes patients is small. In addition, in both paper III and 
IV we performed sensitivity analyses with a stricter LADA definition (i.e. no insulin within 
one year of diagnosis) and found similar results. 
4.2.5 Questionnaire information 
At baseline, participants answered self-administrated questionnaires including items on 
smoking status, alcohol intake, education, leisure time physical activity and FHD.  
Information on diabetes in first-degree relatives was available from HUNT1 (siblings), 
HUNT2 and HUNT3 (parents, siblings, children) and those with self-reported FHD in any of 
the three surveys were considered exposed. A detailed description of procedures and methods 
is found at: http://www.ntnu.edu/hunt. 
4.2.6 Anthropometrical information 
Participants’ body measurements were obtained by trained nurses at the baseline clinical 
examination (HUNT1 or/and HUNT2). 
Body mass index (Paper III, IV) 
BMI (kg/m
2
) was calculated from weight (rounded to nearest half kilo) and height (in whole 
centimetres) with participants wearing light clothing and no shoes and categorized as in 
ESTRID (WHO standard). 
Waist-to-hip and waist-to-height ratio (Paper III) 
Waist and hip circumference and height were used to calculate waist-to-hip ratio (WHR) and 
waist-to-height ratio (WHtR), two measures of abdominal obesity that has been suggested to 
best predict risk of diabetes [169]. Waist circumference was measured at the height of the 
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umbilicus and hip circumference at the thickest part of the hip. The measures were 
dichotomized according to previously used risk levels: WHR <0.85 vs. ≥0.85 (women) and 
<0.90 vs. ≥0.90 (men) and WHtR <0.50 vs. ≥0.50 [169]. 
4.2.7 Genetic information 
DNA samples were available from the HUNT biobank and genotyped for SNPs associated 
with HLA (rs2854275, rs9273363, rs9272346), TCF7L2 (rs7903146) and FTO (rs9939609) 
with HumanCoreExome arrays (Illumina, San Diego, CA, USA 
https://www.ntnu.no/hunt/gwas-data). Imputation, was performed with Minimac3 (v2.0.1, 
http://genome.sph.umich.edu/wiki/Minimac3) from a customized Haplotype Reference 
consortium release 1.1 (HRC v1.1). All analyses were computed at the NTNU Genomic Core 
Facility in Trondheim. The HLA SNPs were chosen based on previous literature [18, 68, 166] 
and participants were categorized as having HLA high-risk genotype if carrying at least one 
of the risk variants; rs2854275 (TT/TG), rs9273363 (AA) or rs9272346 (AA). 
 
4.3 STATISTICAL ANALYSES 
Conditional logistic regression analysis (Paper I, II, III, IV) 
Data from ESTRID was analysed with classical case-control methodology, where the 
proportion of exposed cases is compared with proportion of exposed controls. This was done 
by calculating odds ratios (OR) and 95% confidence intervals (CI) of LADA and type 2 
diabetes associated with birthweight, FHD, BMI and genotypes of interest using conditional 
logistic regression analysis (matched on date of inclusion and county). By applying incidence 
density sampling [163] i.e. by enrolment of incident cases of diabetes and controls randomly 
sampled from the source population at risk (eligible to become a case during the remainder of 
the study time) at the same time as the cases, the OR yields a direct estimate of the incidence 
rate ratio (IRR). In paper I, we performed both matched and unmatched analyses but chose to 
report ORs from the unmatched model as there was no appreciable difference between the 
analyses. In study IV, cases and genetic controls from EIRA were post-matched based on age 
(in 5 year strata) and sex. 
Restricted cubic spline regression analysis (Paper III) 
Restricted cubic spline models were applied in paper III (ESTRID data) in order to assess 
BMI (per unit increase) in relation to the risk of LADA and type 2 diabetes without making 
any assumption about linearity i.e. by fitting a smooth line which is allowed to vary over the 
whole range of BMI [170]. 
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Linear regression (Paper III) 
For the ESTRID data in paper III we also used linear regression models to estimate the 
association between BMI and degree of insulin resistance (logHOMA-IR) and levels of 
logGADA (applied with logarithmic transformation due to a non-linear association and 
differences in variance). 
Population attributable  risk (Paper III) 
In Paper III, to assess what proportion of cases of LADA and type 2 diabetes that can be 
attributed to overweight and obesity we calculated population attributable risk (PAR) by 
applying the formula:  
𝑝(1 − [1/𝑅𝑅]) 
Where p is the prevalence (%) of the risk factor of interest among cases and RR is the 
adjusted effect estimate (OR or HR) [171]. 
Cox proportional hazards regression analysis (Paper III, IV) 
In the prospective data from HUNT, we modelled Cox proportional hazards regression with 
age as underlying time-scale to estimate hazard ratios (HR) with 95% CI of LADA and type 2 
diabetes associated with overweight, obesity and genes. For individuals participating at all 
three surveys (with baseline measurements from both HUNT1 and HUNT2), time-dependent 
variables were used such that exposure and covariate information were updated the second 
time of participation. Person-years of follow-up were accumulated from age at baseline 
(HUNT1 [1984] or HUNT2 [1995]) until age at onset of diabetes, death or age at follow-up 
(in HUNT2 [1997] or HUNT3 [2008]), whichever came first.   
Interaction (Paper I, III, IV) 
In this thesis we are referring to interaction on an additive scale i.e. interaction is present if 
the net effect of two independent risk factors exceeds the risk of each factor assessed 
independently (super additive association). In study I, interaction was calculated with relative 
excess risk due to interaction (RERI) with 95% CI for those with joint exposures (low 
birthweight and overweight).Whereas attributable proportion (AP) due to interaction with 
95% CI was reported for doubly exposed individuals in study III (overweight and FHD) and 
in study IV (high-risk genotype and overweight) according to the following formulas:  
𝑅𝐸𝑅𝐼 = 𝑅𝑅11 − 𝑅𝑅10 − 𝑅𝑅01 + 𝑅𝑅00  
𝐴𝑃 = 𝑅𝐸𝑅𝐼 / 𝑅𝑅11 
Where RR is relative risk associated with the outcome when both (RR
11
), either (RR
10
 or 
RR
01
), or none (RR
00
) of the exposures are present. Positive interaction is said to be present if 
RERI or AP > 0. 
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Meta-analysis (Paper IV) 
In paper IV, RRs and APs from the separate BMI-gene analyses in ESTRID and HUNT were 
pooled to reduce random variation. The pooling was performed with EpiNet meta-analysis 
tool (freely available from www.epinet.se) using the inverse variance method and a fixed 
model approach [172]. 
Stratified analysis (Paper II, III, IV) 
We also performed stratified analyses were we divided the LADA cases by median GADA 
level, referred to in the thesis as LADA
low
 (<median) and LADA
high
 (≥median). The median 
GADA-level was 177.5 IU/ml in paper II, 196.0 IU/ml (ESTRID) and 134.4 IU/ml (HUNT) 
in paper III and 206 IU/ml (ESTRID) and 151 IU/ml (HUNT) in paper IV. 
 
Stata Statistical Software 14 (StataCorp, College Station, TX, USA) was used for calculating 
splines. All other analyses were calculated with Statistical Analysis Software (SAS) 9.4 (SAS 
Institute, Cary, NC, USA). 
 
4.4 ETHICAL CONSIDERATIONS  
Informed consent was obtained from all participants in ESTRID, EIRA and HUNT and the 
studies have been approved by ethical committees: ESTRID by the Ethical review board in 
Stockholm, including an extended approval for inclusion of EIRA controls, and HUNT, by 
the Norwegian Data Inspectorate and Regional Committee for Medical Research Ethics.
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5 MAIN RESULTS
5.1 POPULATION CHARACTERISTICS
In both cohorts (Table 5.1), comparing individuals with LADA and type 2 diabetes, the
former group had inferior insulin secretion (C-peptide), were more often treated with insulin
and had greater proportion of HLA high-risk variants. In ESTRID, the LADA patients were
also younger, leaner (BMI) and less insulin resistant (HOMA-IR) than patients with type 2
diabetes. Differences between patient groups in HUNT were smaller i.e. degree of insulin
resistance and mean BMI were similar although LADA patients had less abdominal obesity
(mean WHR).
5.2 BIRTHWEIGHT, LADA AND TYPE 2 DIABETES (PAPER I)
In paper I, we explored the association between birthweight, LADA and type 2 diabetes. We
found that low birthweight was inversely associated with both subtypes of diabetes: OR
increased with 52% per every kg reduction in birthweight (OR 1.52, 95% CI 1.12-2.08) for
LADA and with 58% for type 2 diabetes (OR 1.58, 95% CI 1.23-2.04). Among participants
weighing <3 kg compared with ≥4 kg at birth, OR was estimated at 2.38 (95% CI 1.23-4.60)
for LADA and at 2.37 (95% CI 1.37-4.10) for type 2 diabetes. There seemed to be little
impact from FHD on these risk-estimates, OR only changed marginally after adjustment (See
paper I, table 2 for details). The highest risk was found in those exposed to both low
birthweight and overweight; for LADA the OR was estimated at 3.26 (95% CI 1.69-6.29) and
for type 2 diabetes at 39.93 (95% CI 19.27-82.71) when comparing to those with birthweights
≥3 kg and with normal weight. No interaction was found for LADA (Figure 5.1), however for
type 2 diabetes there was a 25-fold excess risk attributed to the joint effect of low birthweight
and overweight (Figure 5.1).
Figure 5.1 Combinations of low birthweight (< 3kg) and overweight (BMI ≥25) for LADA (left,
pink bars) and type 2 diabetes (right, blue bars). Reference is birthweight (≥ 3 kg) and normal weight
(BMI <25). The hatched area represents the relative excess risk due to interaction (RERI) for those
with both risk factors. Models were adjusted for age, sex and FHD.
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Table 5.1 Characteristics of the study participants from ESTRID and HUNT (included in paper III in the thesis) and genetic controls from the EIRA study 
(included in paper IV in the thesis).
 
HUNT    ESTRID   
  
Characteristics 
No 
diabetes 
Type 2 
diabetes  
LADA P 
 a
 Controls 
Type 2  
diabetes 
LADA P 
a
 
Genetic  
controls  
No. of individuals 54,440 2,002 147  1,704 1,420 425  2,656 
Women, % 53.2 47.3 51.7 0.3028 51.9 39.2 45.7 0.0181 72.4 
Mean age (years) at diagnosis, (SD) 
b
 – 60.9 (10.9) 59.9 (11.1) 0.3039 58.4 (13.5) 63.2 (10.3) 59.0 (12.3) <.0001 56.6 (9.4) 
Mean age (years) at baseline (HUNT), (SD)  48.3 (15.8) 54.8 (11.0) 54.4 (11.2) 0.6928 – – – – – 
Mean BMI (kg/m
2
), (SD) 25.5 (3.8) 29.8 (4.5) 29.2 (4.9) 0.1704 25.9 (4.2) 31.2 (5.4) 28.1 (5.3) <.0001 25.5 (4.1) 
Mean waist-to-hip ratio, (SD) 
c
  0.84 (0.08) 0.90 (0.07) 0.87 (0.07) 0.0260 – – – – – 
Any first-degree FHD, % 24.2 57.1 48.3 0.0379 24.4 49.8 45.2 0.0951 – 
FHD-T2D, %
 
 – – – – 22.65 47.61 36.71 <.0001 – 
FHD-T1D, %
 
 – – – – 2.58 5.00 11.29 <.0001 – 
With insulin treatment, % – 3.4 17.3 <.0001 – 5.9 41.2 <.0001 – 
Median C-peptide (nmol/l), (IQR) – 0.86 (0.60) 0.57 (0.78) <.0001 – 1.20 (0.65) 0.69 (0.67) <.0001 – 
Median GADA, (IU/ml), (IQR) – – 134.4 (521.4) – – – 196.0 (224.0) – – 
Median HOMA-IR, (IQR) – 2.20 (1.60) 2.10 (1.70) 0.1119 – 3.50 (2.20) 2.70 (2.60) <.0001 – 
Median HOMA-β, (IQR) – 64.5 (49.2) 59.0 (50.8) 0.4109 – 68.1 (49.8) 37.8 (53.6) <.0001 – 
HLA high-risk genotype, % 
d
 42.5 40.7 60.3 <0.0001 – 31.4 61.2 <.0001 33.0 
TCF7L2-rs7903146, % 
e
 44.2 54.9 44.3 0.0186 – 52.1 51.8 0.7795 45.8 
FTO-rs9939609, % 
f
 65.9 69.2 76.3 0.0847 – 67.5 66.3 0.5156 64.3 
a) P for difference between LADA and type 2 diabetes. b) Age at inclusion for control participants. c) Information only available from baseline at HUNT2 (1995–1997).  
d) HLA high-risk: DR4/4, DR3/3, DR3/4, DR3/4-DQ8, DR4/4-DQ8 or DR4/X-DQ8. e) Proportion with the TT/TC genotype. f) Proportion with the AA/AT genotype.  
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5.3 FAMILY HISTORY OF DIABETES, LADA AND TYPE 2 DIABETES (PAPER
II)
In study II we explored LADA and type 2 diabetes in relation to FHD and found that first-
degree FHD more than doubled the risk of LADA (OR 2.22, 95% CI 1.73–2.85) and type 2
diabetes 2.66 (95% CI 2.17–3.28) (Figure 5.2) when compared to those without FHD. We
additionally found that the association with LADA was much stronger had the relative type 1
diabetes with OR elevated 6-fold (OR 5.75; 95% CI 3.23-10.25). Still, LADA was clearly
associated also with FHD-T2D (OR 1.89; 95% CI 1.45-2.47). Type 2 diabetes was foremost
associated with FHD-T2D (Figure 5.2). For LADA, FHD-T1D vs. FHD-T2D was associated
with a phenotype that were closer to that of type 1 diabetes such that GADA titres were
higher (250 vs. 104 IU/mL ),while C-peptide levels (0.65 vs. 0.91 nmol/L) and prevalence of
HLA low-risk genotypes (5.0% vs. 28.6%) were lower.
Figure 5.2 RR and 95% CI for LADA and type 2 diabetes in relation to FHD (reference; no FHD),
using data from ESTRID, and genotypes of HLA, TCF7L2 and FTO, using pooled data from ESTRID
and HUNT. Analyses of FHD were adjusted for age, sex, BMI, education and smoking. In addition,
FHD–T1D was adjusted for FHD–T2D and vice versa. Analyses of genotypes were adjusted for age
and sex.
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5.4 OVERWEIGHT AND OBESITY IN RELATION TO LADA AND TYPE 2
DIABETES (PAPER III)
Results from ESTRID indicated that obesity, compared with normal weight, was associated
with a 3-fold increased risk of LADA (OR 2.93, 95% CI, 2.17-3.97) and a 19-fold increased
risk of type 2 diabetes (OR 18.88 (95% CI 14.29-24.94). The relationship with LADA was
seen foremost in LADAlow (OR 4.25; 95% CI 2.76-6.52) yet, present in LADAhigh (OR 2.14;
95% CI 1.42-3.24). Data from HUNT confirmed these results suggesting even stronger
associations (Figure 5.3). Data from HUNT2 further indicated that abdominal obesity (WHR
and WHtR) augments the risk of LADA 2-3 fold. Corresponding estimates for type 2 diabetes
are found in figure 5.3. The non-linear association between BMI and diabetes, presented with
splines, can be found in paper III.
Figure 5.3 ORs (ESTRID) and HRs (HUNT) with 95% CI of LADA and type 2 diabetes in relation
to overweight (BMI 25–29.9) and obesity (BMI ≥30) vs. normal weight (BMI <25) and HRs for
LADA and type 2 diabetes in relation to WHR (<0.85 vs. ≥0.85 [women] and <0.90 vs. ≥0.90 [men])
and WHtR (<0.50 vs. ≥0.50) using data from HUNT2. All models were adjusted for age, sex, FHD,
smoking and physical activity.
The combination of BMI ≥25 and FHD conferred the highest risk of LADA and type 2
diabetes (Figure 5.4). No interaction was observed for LADA in ESTRID (AP=0.06; 95% CI
−0.25-0.37) however, results from HUNT indicated that 37% (AP=0.37, 95% CI 0.10-0.64)
of the LADA cases can be attributed to the interaction between overweight and FHD. For
type 2 diabetes, interaction was seen irrespective of data (Figure 5.4).
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Figure 5.4 Combinations of overweight/obesity (BMI ≥25) and FHD in relation to the risk of LADA
in ESTRID (A), LADA in HUNT (B), type 2 diabetes in ESTRID (C) and type 2 diabetes in HUNT
(D). Reference is normal weight (BMI <25) and no FHD. The hatched area represents the attributable
risk due to interaction (AP). Models were adjusted for age, sex, smoking and physical activity.
Obese vs. normal weight individuals with LADA displayed a more type 2-like phenotype
indicated by greater levels of C-peptide and lower proportion of insulin treatment. In both
studies, BMI was also positively associated with insulin resistance (HOMA-IR). Contrary,
BMI was inversely associated with GADA in ESTRID but this association was weak in
HUNT (details can be found in paper III). Moreover, calculation of PAR suggested that 31-
56% of all LADA cases and 70-82% of all type 2 diabetes cases can be attributed to
overweight/obesity.
5.5 BMI-GENE INTERACTION, LADA AND TYPE 2 DIABETES (PAPER IV)
In the fourth study, we pooled risk estimates from ESTRID and HUNT and continued to
explore the interaction between BMI and heredity that was indicated in paper III, here
focusing on high-risk genotypes of HLA, TCF7L2 and FTO. Study-specific risk estimates
can be found in paper IV. We first studied the association between diabetes and each variant
separately; HLA high-risk genotypes were strongly associated with LADA in both cohorts
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(RRpooled 2.74; 95% CI 2.23-3.36) whereas TCF7L2 was only associated with LADA in
ESTRID and FTO only with LADA in HUNT (Figure 5.2). However in the pooled analysis,
an overall association was seen between LADAlow and high-risk genotypes of both TCF7L2
and FTO (results for the stratified LADA analyses are found in the supplementary material of
paper IV).
Moreover, the combination of overweight and each of the high-risk variants conferred an
increased risk of LADA with RRpooled of 7.59 (95% CI 5.27-10.93) for HLA, 2.65 (95% CI
1.97-3.56) for TCF7L2 and 2.21 (95% CI 1.60-3.07) for FTO (Figure 5.6). We also found
interaction between overweight and HLA (AP 0.29; 95% CI 0.10-0.47) TCF7L2 (0.31; 95%
CI 0.09-0.52) and FTO (AP 0.38, 95% CI 0.15-0.61). Using the Swedish data, the strongest
risk was observed in overweight individuals with the DR4/4 genotype (RR 26.76, 95% CI
15.42-46.43, AP 0.58, 95% CI 0.32-0.83. These results indicate that about 29-38% of the
doubled exposed LADA cases may be prevented by maintaining a healthy weight. Type 2
diabetes was associated with both TCF7L2 and FTO but not with HLA (Figure 5.2). There
was a significant interaction between overweight and TCF7L2 (AP 0.26; 95% CI 0.19-0.33),
but not between overweight and high-risk genotypes of HLA or FTO (Figure 5.6).
A B
C
Figure 5.6 Combinations of
overweight/obesity (BMI ≥25) and genotypes
of HLA high vs. low/intermediate risk
genotypes (A), TCF7L2 TT/TC vs. CC (B) and
FTO AA/AT vs. TT (C) in relation to the risk
of LADA (pink bars) and type 2 diabetes (blue
bars) using pooled data from ESTRID and
HUNT. Reference is normal weight (BMI
<25) and not carrying the risk genotype. The
hatched area represents the attributable risk
due to interaction (AP). The dotted area
represents negative AP.
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6 DISCUSSION 
6.1 SUMMARY OF MAIN FINDINGS AND INTERPRETATIONS  
The purpose of this thesis was to explore how FHD, low birthweight, overweight/obesity, and 
the potential interaction between these factors, influence the risk of LADA compared to type 
2 diabetes. Regarding heritability, our findings indicate that FHD of type 1 diabetes confers 
the highest risk of LADA, but that the risk is also elevated for those with FHD-T2D. 
Likewise, there was a stronger link between LADA and HLA high-risk genotypes, associated 
with type 1 diabetes and autoimmunity, than between LADA and TCF7L2 and FTO 
genotypes associated with type 2 diabetes. These findings support the notion that LADA is 
genetically closer to type 1 than type 2 diabetes [16]. We further observed that 
overweight/obesity increase the risk of LADA, and that the combination of overweight and 
FHD or HLA high-risk variants, in particularly the DR4/4 genotype, dramatically increased 
the risk of LADA. Additionally, there was interaction between overweight and risk variants 
of the TCF7L2 and FTO genotypes in relation to LADA and with TCF7L2 in relation to type 
2 diabetes. Our findings further suggest that low birthweight is associated with increased risk 
of LADA as well as type 2 diabetes, particularly in combination with adult overweight. 
Overall, the results of this thesis suggest that LADA essentially is a consequence of genetic 
predisposition towards autoimmunity along with environmental exposures that promote 
insulin resistance. 
6.2 HEREDITY 
Using data from ESTRID, we first confirmed previous results showing that FHD is 
associated with increased risk of LADA [119, 173] and type 2 diabetes [112]. We further 
observed that the risk of LADA is considerably higher for individuals with first-degree FHD-
T1D vs FHD-T2D, although the risk was clearly raised also for the latter group. This is 
concordant with cross-sectional studies indicating that the prevalence of FHD-T2D is as high 
in LADA as in type 2 diabetes, whereas FHD-T1D is much more prevalent in LADA [124]. 
Genetic analysis from paper IV, where we incorporated data from both ESTRID and HUNT, 
support this view; HLA high-risk genotypes were strongly associated with LADA in both 
studies. Likewise, the abundance of genetic studies during the last decades indicate that 
genetic susceptibility in LADA stems foremost from HLA genotypes associated with type 1 
diabetes [69, 70].  
Our results for the type 2 diabetes associated genes were contradictive and much weaker. A 
genetic overlap between LADA and type 2 diabetes is debated and while some find an 
association [66, 67, 72, 73], others do not [68, 69]. Stratification by median GADA titre 
however, revealed an overall association with both the TCF7L2 and FTO risk genotypes in 
LADA with lower GADA level, which is in line with what has been reported by previous 
studies [67, 72].  It is likely that genes associated with type 2 diabetes are more important for 
less autoimmune, type 2-like LADA. This is further supported by a recent study that found 
that single GADA positive children with the TCF7L2 genotype less often converted to 
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multiple antibody status than those without the risk genotype [174]. Mechanistically the FTO 
gene is associated with increased obesity, which may explain why the association with 
LADA was seen only in HUNT; these patients had both higher BMI and higher prevalence of 
the risk variant compared with LADA patients in ESTRID (paper IV, table 1). However, the 
majority of genes associated with type 2 diabetes susceptibility, including TCF7L2, primarily 
impact β-cell function and secretion [59, 61] rather than worsening peripheral insulin 
resistance. Similarly, in individuals with FHD-T2D, β-cell dysfunction is present long before 
the development of hyperglycaemia [175]. However, as the risk is modest it is not clear how 
much these risk variants per se actually contribute to the aetiology of LADA, even in case of 
mild autoimmunity.  
Consistent with the above, the risk of type 2 diabetes was primarily associated with FHD–
T2D and patients with FHD had lower levels of C-peptide than those without FHD [12,35].  
We could further confirm that type 2 diabetes is associated with TCF7L2 and FTO but not 
with HLA [16]. Notably, as heritability cannot completely be explained by genetic 
susceptibility [57], some of the association between LADA and FHD is likely a result of 
lifestyle factors shared within families, especially for individuals with FHD-T2D. Still, 
adjusting for BMI and physical activity had little impact on the association, which is in line 
with present and previous reports for type 2 diabetes [112]. This may implicate that 
epigenetic alterations, e.g. parental exposures at time of conception [126], underpin part of 
the association. 
6.3 OVERWEIGHT AND OBESITY 
Overweight/obesity was shown to be strongly associated with increased risk of LADA both 
in the Swedish case-control data and in the prospective data from Norway. The risk was less 
pronounced compared with type 2 diabetes which supports the belief that insulin resistance 
underlie the pathogenesis but is a less important factor for LADA than for type 2 diabetes 
[16]. In line with this, calculation of PAR suggested that a large part of the LADA patients 
may be prevented by keeping a normal weight but that this proportion is smaller than for type 
2 diabetes. The association between LADA and obesity was strongest in less autoimmune 
LADA, and these patients displayed a more type 2-like phenotype with less HLA high-risk 
genotypes and better β-cell function. Notably, we did observe an increased risk also in the 
most autoimmune LADA group. In keeping with our findings an elevated risk has been seen 
both in children [87] and adults [88] with type 1 diabetes. Pathologically, our results favour 
insulin resistance as the primary pathway; there was a positive association between BMI and 
HOMA-IR indices. In contrast, an inverse relationship was observed with level of GADA 
which has been reported previously both for LADA [71] and for type 1 diabetes [176]. As 
insulin resistance amplify the need for insulin [2], it is conceivable that β-cells in people with 
autoimmunity and an already impaired insulin release will not be able to compensate for the 
increased requirement following obesity. This is compatible with the accelerator hypothesis 
which proposes that insulin resistance exhaust the β-cells and further, that insulin resistance is 
the common denominator for type 2 diabetes and autoimmune diabetes [143]. However, this 
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does not rule out a possible link between obesity and autoimmunity in LADA; it has been 
suggested that obesity induced inflammation mediates β-cell stress and increases antigen 
presentation, which may evoke an autoimmune reaction in individuals with a genetic 
predisposition [177, 178].  
We further investigated potential interaction between overweight, FHD and genes in relation 
to diabetes. Indeed the strongest risk of both LADA and type 2 diabetes was seen in those 
exposed jointly to FHD and overweight. For LADA, the combined effect of overweight and 
HLA high-risk genotypes conferred the by far highest risk. In addition, a dramatic interaction 
between HLA high-risk genes and overweight was observed which was most evident for 
those with the DR4/4 variant. Previous studies of type 1 diabetes in children [153, 179] and 
of multiple sclerosis [154] support our findings of a synergistic effect between BMI and HLA 
risk-genotypes. Additionally, there was interaction between overweight and TCF7L2 and 
FTO in relation to LADA. The interaction with TCF7L2 was also confirmed in relation to 
type 2 diabetes. This in line with earlier studies of type 2 diabetes [155, 156], reporting 
interaction between overweight and a genetic risk score. Moreover, a strong interaction 
between TCF7L2 and obesity was recently reported in a Chinese population [157]. 
It is plausible that the double burden of carrying both HLA genes, associated with 
autoimmunity, and obesity, which besides leading to reduced insulin sensitivity puts an extra 
load on the β-cells, further intensifies the risk of LADA. Similarly, in individuals carrying the 
TCF7L2 genotype and a genetically induced insulin deficiency (which alone only marginally 
increases the risk), the risk of LADA exacerbates when combined with insulin resistance. The 
observed interaction between overweight and FTO in relation to LADA indicated that the risk 
associated with FTO is only elevated when combined with overweight. This is in keeping 
with previous reports suggesting that the risk allele increase the risk of obesity [64], while in 
those who stay physically active, the risk attenuates [158]. There was no interaction between 
FTO and overweight for type 2 diabetes which may be due to overweight being a much more 
prominent risk factor for type 2 diabetes than for LADA even without genetic risk. 
From the above, it can be hypothesised that genes and environment follow a reciprocal 
relationship in the aetiology of LADA such that individuals with low (HLA) genetic 
susceptibility demand more lifestyle factors promoting insulin resistance for manifest disease. 
In the presence of a high genetic load, insulin resistance plays less of a critical role. However, 
when these factors are present together the risk rises “through the roof”. Interaction is also 
useful from a public health perspective, i.e. by identifying subgroups of individuals with 
additional risk, preventive measures can be undertaken more efficiently. Importantly, our 
findings suggest that LADA, in line with type 2 diabetes, may be prevented with weight 
management. It is noteworthy that this seems to apply also to individuals with genetic 
susceptibility. 
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6.4 BIRTHWEIGHT 
Using data from ESTRID, we found an inverse relationship between birthweight and LADA 
such that low but not high birthweight was associated with excess risk. This is the first study 
investigating birthweight in relation to LADA, but the result fits with a large amount of type 
2 diabetes studies [98]. Our results for type 2 diabetes were also in line with these earlier 
findings. The study was hampered by the small number of participants and it is possible that 
also high birthweight, mediated by maternal diabetes/obesity during pregnancy, would confer 
risk of LADA in a larger sample. Especially since high birthweight has been associated with 
both type 1 [85, 86, 128] and type 2 diabetes [99, 100]. Supporting this notion, the association 
with low birthweight was strengthened after excluding those reporting maternal diabetes. 
However, adjusting for FHD did not impact the results, neither for LADA nor for type 2 
diabetes. This implies that the association between LADA and low birthweight is related to 
the in utero environment rather than being genetically determined. A considerable body of 
evidence supports this possibility [126], e.g. maternal malnutrition during pregnancy or 
paternal metabolic disease before conception and during spermatogenesis may adversely 
impact the metabolic health of offspring in later life [180]. The combination of low 
birthweight and adult overweight further increased the risk of LADA and type 2 diabetes, 
which particularly favours the thrifty phenotype hypothesis [136]. Clearly, the findings for 
LADA need to be extended and replicated and even though the topic of in utero environment 
has been investigated intensely, the field of epigenetics is still in its infancy and many more 
questions need to be addressed before drawing any conclusions.  
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6.5 METHODOLOGICAL CONSIDERATIONS 
6.5.1 Random error 
The presence of random variation should be kept in mind when interpreting data and in 
general, small numbers increases the risk of imprecise results. Confidence intervals in 
stratified analyses were occasionally wide and overlapping. Thus, interpretation of risk 
magnitudes and results from subgroup analyses should be made with some caution. This is 
foremost a concern in paper I in which half of the study population was lost due to 
participants not recalling their birthweight. The results were based on cases and controls 
recruited between 2010 and 2014. When re-analysing the data with cases recruited until 2017, 
the same result is obtained. It is of course still important to replicate the findings in other 
materials. 
6.5.2 Systematic errors 
6.5.2.1 Selection bias 
Selection bias occurs if participation in a study is related, in a non-random way, to the 
exposure and disease under study. In a case-control study, the key feature of the controls is to 
mirror exposure frequency in the study base. If this is violated, selection bias is introduced 
which could either over- or underestimate the effect estimates. Controls were recruited 
continuously and randomly (incidence density sampling) from the same population that 
produced the cases. The method has a high validity [163] but a spurious association may arise 
if participating controls differed from those who did not. For instance, individuals with higher 
education are generally overrepresented among responders. Higher education is in turn 
associated with a healthier lifestyle, why it can be expected that participants tend to be leaner 
and more active compared to the general population. Response rate among controls in 
ESTRID is 62%, to estimate if this is a representative sample of the study base we compared 
our controls to the general population in Skåne with regard to level of education and found 
that it was similar (http://www.statistikdatabasen.scb.se). Moreover, the proportion of obesity 
among our controls and the general population of Skåne (16-84 years) is the same (15%). 
However, it should be noted that this estimate is based on data from the national public health 
survey with only 42% response rate (https://www.folkhalsomyndigheten.se). The genetic 
controls from EIRA were slightly leaner (12% were obese). This could have led us to 
overestimate the results in paper IV. Still, the overall association with overweight and obesity 
is in line with results from paper III where we used the controls recruited within ESTRID, 
suggesting that this did not impact the results to any large extent.  
The case response rate in ESTRID was high (83% for LADA and 79% for type 2 diabetes). 
Even so, an additional concern is whether cases recruited from the ANDIS and ANDiU 
registers in Skåne and Uppsala differ from those not covered by these registers. Still, the 
absolute majority of the patients in ESTRID were recruited from ANDIS, which at present 
covers >90% all eligible patients in Skåne County [18]. Out of these ~95% of the LADA 
 38 
cases are invited to participate in ESTRID. Furthermore, there is nothing to suggest that 
health care centres not covered by these registers differ systematically from those included. 
Internal non-response may also be a problem if cases and controls differ in that respect. 
Especially in paper I were only 45% of the participants knew their birthweight. However, 
there is no reason to suspect that birthweight would be linked to non-response. Importantly, 
response rates were similar among cases and controls. We also called all participants with 
missing information and could confirm that these people did not know their birthweight. In 
addition, when we compare register-based data of the controls with and without self-report (n 
= 81), we found that those without this information have slightly higher mean birthweight, 
(3.55 kg vs. 3.43 kg). If anything, this suggests that we have underestimated the association 
between low birthweight and diabetes. Notably, our results for type 2 diabetes were in line 
with a large number of register-based studies [98].  
In HUNT, response rate dropped during the course of the study, from 91% in the first survey 
to 54% in the last one. Thus loss to follow-up may be a problem and may affect the 
association with BMI if dropping out is linked to both exposure and disease (e.g. if obese 
individuals with diabetes are less likely to attend the follow-up study or died before follow-
up). In such case, the association would most likely be underestimated. In support of low 
selection bias, validation studies where re-attenders were compared to those who did not 
attend the follow-up showed that the groups were similar with regard to most health 
characteristics.  However, older participants who discontinued their participation had a higher 
rate of co-morbidities compared to participants in the same age [167, 181]. 
6.5.2.2 Misclassification of exposure 
The self-reported exposure information is problematic. In ESTRID, were we used a 
retrospective approach, this may lead to a differential exposure misclassification if cases 
remember and report birthweight, FHD and BMI exposures differently than controls. This 
could either under- or overestimate our associations. By using incident cases approached in 
close proximity to diagnosis and by emphasizing the importance of reporting lifestyle 
according to the year prior to disease onset, the likelihood of response bias should be reduced. 
Still, the self-reported BMI information in ESTRID is a limitation. As pointed out by 
Rothman and others [182, 183] the most likely scenario would be that responders underreport 
their current weight (especially if obese) and over report height. The implication is that we 
will underestimate the association between overweight/obesity and diabetes, as long as cases 
and controls do not differ in their degree of underreporting. If cases underreport more, e.g. 
due to the fact that they lost weight following diagnoses and report accordingly, this would 
lead us to underestimate the association with BMI further. In this context, it is also 
noteworthy that among cases, self-reported BMI information (weight and height) was highly 
correlated (r=0.92, p <0.0001) with BMI calculated at diagnosis (information available from 
ANDIS). Importantly we could confirm our results using objectively obtained information 
from the HUNT study. 
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Likewise, for individuals born after 1973, the self-reported birthweight information was 
validated against register data with a very good result; r=0.86 (p <0.0001). We were not able 
to validate the self-reported information for older participants, whom at the same time may 
have reported less accurate information. To handle this we performed separate analysis for 
individuals aged ≥60 years.  These estimations only marginally changed the results, 
indicating a non-biased result. In support are other studies demonstrating a high validity of 
birthweight information also for older individuals [98, 140, 184].  
With regard to the self-reported information on FHD, it is possible that cases are more aware 
of relatives’ diabetes status which would lead us to overestimate the association with 
diabetes. For the same reason, relatives may be more prone to seek medical care if they 
experience diabetes like symptoms. However, cases are approached close to diagnosis which 
reduces the time window for raised awareness among the relatives. Also relatives’ age at 
onset and insulin treatment, used to determine FHD-T1D vs FHD-T2D, was based on self-
reported information from the participants. Our rather crude classification may have led 
relatives with autoimmune diabetes and onset after 40 years of age to be classified as having 
type 2 diabetes. This could explain part of the association between LADA and FHD-T2D. 
However, using a more stringent classification of FHD-T2D (≥40 years and no insulin 
treatment) did not change the association.  
6.5.2.3 Misclassification of disease 
Patients in ESTRID were diagnosed within the health care system. The self-reported diabetes 
in HUNT could potentially be a problem. However validation studies, comparing 
questionnaire data with medical records of the patients showed that the methods were highly 
correlated [168]. Nevertheless, individuals with diabetes can sometimes be asymptomatic for 
many years before diagnosis. Consequently, it is possible that we have cases of undiagnosed 
diabetes among the controls/individuals not reporting diabetes. If the likelihood of being 
diagnosed is related to exposure i.e. birthweight, FHD and BMI, this may bias (overestimate) 
the relative risk estimates in present thesis. On the other hand, the rate of undiagnosed 
diabetes in HUNT is reportedly low (0.3%) [168]. In ESTRID, one can assume that controls 
with undiagnosed diabetes would be more similar to the cases in which case, we would have 
underestimated the associations.  
The possibility of false positive LADA patients is a concern, in particularly in LADA patients 
with low GADA levels. To separate LADA patients from type 2 diabetes we used GADA, 
which has been shown to be the antibody that best predicts autoimmunity and progression to 
disease [25]. In ESTRID the method has high specificity: 98%. This implies that 2% of type 2 
diabetes cases may be misclassified as cases of LADA. Simulations where we attempted to 
remove a proportion of obese subjects, hypothesized to be cases of type 2 diabetes, indicate 
that this potential misclassification is not enough to remove the risk of LADA associated with 
excessive weight. Furthermore, the fact that we found an association with obesity and with 
FHD-T2D regardless of GADA level clearly speaks against a large impact from false positive 
LADA patients (i.e. type 2 diabetes patients misclassified as LADA). In addition the 
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association with BMI and LADA was even stronger in HUNT were the specificity of the 
GADA assay was 100%. Most importantly, in both studies there was a clear association 
between HLA high-risk genotypes and LADA with low GADA which is in contrast to what 
we see for type 2 diabetes, supporting the autoimmune nature of this group. Further support, a 
previous study of HUNT indicate a real impact of even low and transient levels of GADA; 
these low GADA individuals displayed lower fasting C-peptide levels [185] than antibody-
negative individuals who were classified as type 2 diabetes. Similarly, in paper III we found a 
higher proportion of insulin treatment among LADA
low
 than in type 2 diabetes patients. 
The sensitivity of the assays (84% in ESTRID and 64% in HUNT) implies that we have false 
negative LADA patients among individuals with type 2 diabetes which may have diluted the 
associations for type 2 diabetes. Moreover, even though GAD is the most common antibody 
in LADA, the use of only one autoimmune marker means that some LADA individuals may 
have been classified as autoantibody negative, i.e. as having type 2 diabetes. In a previous 
study based on HUNT, 99% of LADA cases were positive for GADA and less than 1% was 
exclusively positive for IA-2A or ZnT8A [185]. However, in Action LADA [25], 10% of the 
LADA cases were GADA negative. If we assume that 10% of all LADA cases were positive 
only for these other autoantibodies and thus classified as having type 2 diabetes (by 
multiplying the number of LADA patients by a factor 1.105) this implies that 14 of the type 2 
diabetes patients in HUNT and 42 of the type 2 diabetes patients in ESTRID (numbers from 
paper IV) could be misclassified LADA cases. Also related to false negatives; because 
GADA can disappear after long duration of disease [185] it is possible that LADA patients in 
HUNT, for whom GADA titres were measured several years after diagnosis, appeared 
GADA negative and were consequently included in the type 2 diabetes group. However, 
GADA has been shown to be more stable in LADA compared with type 1 diabetes [16]. 
Most importantly, the lack of association between type 2 diabetes and HLA risk genotypes 
indicates that the proportion of misclassified LADA is most likely small. 
6.5.2.4 Confounding 
A strength of this thesis was that we had the possibility to adjust for a large number of 
potential confounders including physical activity, smoking, alcohol and education. Residual 
confounding or unmeasured confounding should still be kept in mind when interpreting the 
results. For instance in paper I, it would have been interesting to adjust for gestational 
diabetes as this likely diluted our findings for low birthweight. Parental exposures during 
childhood would also be interesting considering both the association with birthweight and 
with FHD, especially for the association with FHD-T2D.  
6.5.3 Generalisability 
Our findings are based on two large population-based studies: The Swedish study aimed at 
covering all incident cases of diabetes in two counties in Sweden together with a random 
sample from the general population. The Norwegian study covered one whole county in 
Norway which has been shown to be a fairly good representative of the rest of Norway [186]. 
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Thus we have no reason to believe that these findings could not be generalised to other 
Nordic countries with similar rates of LADA and exposures under study. With regard to the 
rest of Europe, and other parts of the world where LADA is less prevalent, differences in the 
genetic set-up and pattern of additional risk factors could limit generalisability. Of note, 
estimation of PAR is based on the estimated effect sizes as well as prevalence of overweight 
in the population. In a population with different levels of BMI, the proportion of diabetes 
cases attributed to these risk factors would be different. 
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7 CONCLUSIONS 
The aim of this thesis was to add new knowledge to the aetiology of LADA, by exploring the 
impact of birthweight, overweight and obesity, FHD and genes and their interaction on the 
risk of LADA. Our results suggest that FHD is a strong risk factor. The risk is foremost 
associated with FHD of type 1 diabetes and HLA genotypes promoting autoimmunity, but is 
also associated with FHD of type 2 diabetes. Possibly also with genes promoting type 2 
diabetes and β-cell deficiency in a non-autoimmune way. Moreover, the results indicate that 
overweight and obesity are important risk factors in relation to LADA, probably mediated by 
insulin resistance. The risk was especially high in combination with FHD and a considerable 
interaction was observed in individuals with HLA high-risk genotypes. However, interaction 
was also seen in those with risk variants of TCF7L2 and FTO. This indicates that excessive 
weight is a particularly detrimental risk factor for LADA in individuals with genetic 
susceptibility. The results further imply that low birthweight may be as strong risk factor for 
LADA as for type 2 diabetes. The association appeared to be independent of FHD, which 
support the hypothesis that the intrauterine environment rather than genetic factors explain 
the association. The combination of low birthweight and adult overweight seems to be an 
especially important risk factor for LADA which supports the thrifty phenotype hypothesis. 
Taken together, the results from this thesis support that factors linked to insulin resistance and 
type 2 diabetes also constitute risk factors for LADA, while genetic susceptibility is linked 
foremost to genes associated with autoimmunity and type 1 diabetes. These findings 
contribute to the limited but gradually increasing number of studies indicating that lifestyle 
plays an important role in the aetiology of LADA. Notably, under the assumption of 
causality, our results suggest that a large proportion of the LADA cases are attributable to 
excessive weight and may therefore be preventable in a similar way as for type 2 diabetes. 
The results also indicate that lifestyle interventions may be especially beneficial among 
people with HLA high-risk genotypes. Still, these findings are suggestive, and to verify and 
extend these results to other settings is of importance. To evaluate the real preventive 
potential of LADA, intervention studies will be crucial.   
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8 FUTURE PERSPECTIVES 
Risk factors for LADA are still largely an unexplored area. The ESTRID and HUNT data 
materials, which this thesis is based on, provide great opportunities to continue exploring 
potential environmental risk factors that could alter the risk of LADA. Such factors include 
physical inactivity, a large number of dietary factors and many others.   
However, considering that research in this area primarily is based on two Scandinavian 
studies, new research initiatives involving other populations exhibiting other characteristics, 
ethnic backgrounds and genetic set ups, are clearly warranted.  
Further examination of overweight interactions and type 1 diabetes genes outside the HLA 
complex, e.g. INS and PTPN22 and SH2B3, should be considered. Additionally, 
environmental risk factors other than excessive weight would be interesting to explore in a 
gene-environmental setting, some potential candidates being birthweight, physical activity, 
diet, smoking and alcohol consumption. 
Importantly, the best treatment regimen for LADA is still not established and few studies 
have explored long term consequences such as cardiovascular disease. Hence, more remains 
to be investigated in terms of prognosis of LADA. 
Lastly, intervention studies are a necessity to be able to evaluate to what extent LADA 
actually can be prevented by lifestyle modification. High-risk individuals, e.g. persons with 
HLA high-risk genotypes and antibody positivity, could be a good target group for such 
intervention. 
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